Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonazepam for Cannabis Withdrawal and Relapse
NCT02913924Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cannabis use disorder (CUD) comparing Clonazepam with Placebo (2 arms). Primary endpoints: Time to Cannabis Use Relapse at 12 weeks and Proportion of Cannabis Use Days Per Week at 7 weeks. Started Dec 2016; status: completed.
02
Drugs
clonazepam
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT02913924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913924.